A Randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 and Best supportive care vs. Placebo and BSC i the treatment of patients at high risk of residual Hodgkin Lymphoma (HL) following autologous stem cell transplant (ASCT)
|Effective start/end date||8/5/10 → 12/31/20|
- SEAGEN INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.